Wer kennt AXYS Pharna.? - 500 Beiträge pro Seite

[Diamantensucher]

Wer kennt diese Firma und kann mir etwas über mögliche Informationsquellen sagen. Bin an der Aktie interressiert, finde aber bei meinen üblichen Quellen keine / kaum Informationen. Wer weiß etwas und teilt sein Wissen?

Vielen Dank im voraus

Grüsse Diamantensucher

[Diamantensucher]

Scheint wohl keiner zu kennen, schade.

[disciple]

Ist einer der Favoriten im Bereich Biotechnologie des "Zürich Club."

[Trixxie]

Hallo Diamantensucher,
da ich die Frage jetzt erst entdeckt habe, kommt dieser Beitrag natürlich auch verspätet. Meine Infos sind ebenfalls nicht die neuesten, vielleicht helfen sie dir aber weiter.
"Global Biotech Investing" schreibt in der Ausgabe 12/00:
"Der Aktienkurs von AXYS PHARMA soll sich nach Meinung führender New Yorker Analysten in den kommenden Jahren vervielfachen. AXYS Pharma ist eine Biotech-Gesellschaft, die im Jahre 1998 durch einen Merger zwischen ARRIS PHARMA und SEQUANA THERAPEUTICS entstanden ist. Die Gesellschaft konzentriert sich auf die Suche und die Entwicklung neuer Strategien und Behandlungsmöglichkeiten von Krebs. Mit einer Marktkapitalisierung von USD 170 Mio. zählt AXYS zu den absoluten Mini-Gesellschaften, die sich in der Tat schnell einmal vervielfachen können. Morgan Stanley billigt dem Titel ein Kurspotential bis USD 22 zu - das ist mehr als das Vierfache des heutigen Kurses! Fazit: Wir empfehlen AXYS als spekulative Langfristanlage neben CELERA GENOMICS (AXYS PHARMA, EUR 4.90,WKN 888649, Reuters ARRS)!"
Außerdem ist wichtig zu wissen, dass AXYS seit Bestand schwarze Zahlen schreibt, M.Stanleys Erwartungen sich auf die nächsten 3 Jahre bezogen, jedoch im Biotech-Sektor auf längere Zeiträume hin angelegt werden sollte.
Nebenbei: "Global B.I." empfahl in der November-Ausgabe u.a. auch PHARM.PRODUCT DEVELOP. (WKN 899041), die (mit einem Split im letzten Monat) ihren Wert innerhalb von 6 Monaten in aller Stille verdoppelt haben - jedenfalls lassen sich auch zu diesem Unternehmen nirgends Infos finden.
Viel Glück bei der Diamantensuche!!!
Trixxie

[Cafemilk]

Axys Pharma wurde am 13.06.01 von Celera genomics
übernommen. Beide Kurse sind an dem Tage gestiegen
(Axys + 23 %).

[principale]

Vielleicht helfen Dir die Zahlen weiter:

Axys Pharmaceuticals Reports Second Quarter 2001 Financial Results

Updated: Tuesday, August 7, 2001 08:35 AM ET
Email this article to a friend!
Printer-friendly version

Revenues for the six months ended June 30, 2001 were $3.9 million compared to $2.9 million for the same period in 2000. The increase in
the year-to-date amount was due to milestones earned from Merck & Co. (NYSE:MRK, news, msgs) and Aventis S.A. (NYSE:AVE, news,
msgs) in the first quarter of 2001.

Axys also reported a net loss of $13.4 million, or $0.36 per share, for the second quarter of 2001, compared to a profit of $21.4 million or
$.61 per share for the second quarter of 2000. The profit in 2000 reflected the sale of Axys Advanced Technologies to Discovery Partners
International in April 2000. Results for the six months ended June 30, 2001 reflect a net loss of $31.5 million, or $.84 per share, compared
to a net profit of $12.9 million, or $.38 per share, for the same period of 2000. Year-to-date results for 2001 included a $9.0 million
non-cash charge representing the write-off of an investment in Akkadix Corporation.

Second quarter 2001 operating expenses were $12.5 million, compared to $10.9 million incurred in
the comparable quarter last year. Research and development expenses were $8.4 million in second
quarter of 2001, compared to $8.0 million for the same period in 2000. The increase in research and
development expenses was associated with APC 2059 clinical development. General and
administrative expenses were $4.5 million in the second quarter of 2001 compared to $2.9 million for
the same quarter in 2000. The increase in general and administrative expenses is associated with
expenses incurred in connection with the company`s proposed acquisition by Applera Corporation --
Celera Genomics Group (NYSE: CRA, news, msgs).

Applera and Axys announced in a June 13, 2001 press release that they had entered into a definitive
agreement whereby Applera would acquire Axys in a stock-for-stock transaction. Under the terms of
the agreement, each share of Axys common stock will convert into that number of shares of newly
issued Celera Genomics common stock to be determined at the time of the merger, based upon the
market price of Celera Genomics common stock, subject to a collar mechanism.

Following the June 13, 2001 announcement, Applera and Axys made filings to obtain the necessary
regulatory approvals of the proposed acquisition. These included the filing by Applera of a Registration Statement on Form S-4 with the
Securities and Exchange Commission (SEC), which included Axys` preliminary proxy statement relating to the solicitation of shareholder
approval of the acquisition. The parties are currently awaiting comments from the SEC on that Registration Statement. Following
completion of the SEC review, which is the last remaining governmental approval for the acquisition, Axys plans to mail its proxy
statement soliciting shareholder approval. Axys has not yet set a date for its shareholder meeting to approve the acquisition.

About Axys

Axys Pharmaceuticals, Inc., an integrated small molecule drug discovery and development company, has a broad pipeline of products for
chronic therapeutic applications that are partnered with world-class pharmaceutical companies and a proprietary product portfolio in
oncology. Axys also has investments in affiliated businesses that leverage the Axys technologies. Currently, these companies include
Discovery Partners International, Inc. (NasdaqPII, news, msgs), a chemistry services company; and DNA Sciences, a genetics
company. On June 12, 2001, Axys entered into a definitive agreement with Applera Corporation -- Celera Genomics Group whereby
Celera will acquire Axys.

Investors and security holders are advised to read the Form S-4, filed by Applera Corporation with the Securities and Exchange
Commission dated July 9, 2001, for more information regarding the acquisition. It is currently anticipated that the Form S-4/proxy
statement/prospectus will be mailed to stockholders of Axys later this year, seeking their approval of the proposed transaction. Investors
and security holders may obtain a free copy of the proxy statement/prospectus and other documents filed by Axys at the Securities and
Exchange Commission`s web site at www.sec.gov http://www.sec.gov. The proxy statement/prospectus and such other documents may
also be obtained from Axys by directing such request to Axys Pharmaceuticals, 180 Kimball Way, South San Francisco, CA 94080, Attn:
Investor Relations, tel: [phone].

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases
such as "believe," "expect," "anticipate," and "potential," among others. These forward-looking statements are based on Axys` current
expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order
to comply with the terms of the safe harbor, Axys notes that a variety of factors could cause actual results and experience to differ
materially from the anticipated results or other expectations expressed in forward-looking statements within this press release. The
risks and uncertainties include but are not limited to: (1) failure of the merger transaction with Applera to close due to the failure to obtain
regulatory or other approvals; (2) failure of the Axys shareholders to approve the transaction; (3) the risk that the Axys business will not
be integrated successfully into Celera; (4) unanticipated costs of such integration; (5) failure to successfully manage relationships with
customers, suppliers and strategic partners during the pendency of and following the transaction; (6) unproven use of genomics
information to develop products; (7) dependence on computer hardware, software, and internet applications; (8) potential adverse effect
on the Celera Genomics group`s intellectual property protection and the value of its products and services due to public disclosure of
genomics sequence data; (9) government regulation of Celera`s or Axys` products and services; (10) Axys` reliance on the efforts of its
collaborative partners; (11) the risk that Axys` collaborations will not be successful; (12) the risk that clinical trials will not proceed as
anticipated or may not be successful; (13) the risk that Axys will not be successful in entering into new collaborations; (14) market risk
associated with Axys` substantial ownership interest in Discovery Partners International, Inc. and Axys` investments in its other affiliated
businesses; and (15) other factors that might be described from time to time in Axys` filings with the Securities and Exchange
Commission.

Axys and its directors, executive officers and certain members of management and employees may solicit proxies from Axys
shareholders in favor of the adoption of the merger agreement and the transactions associated with the acquisition. A description of any
interests that Axys directors and executive officers have in the acquisition are available in the joint proxy statement/prospectus.

AXYS PHARMACEUTICALS, INC.
Statements of Operations
(unaudited)

Three Months ended Six Months ended
June 30, June 30,
2001 2000* 2001 2000*
--------- -------- ---------- ---------
(in thousands, except per share amounts)

Collaboration and
license revenue $ 820 $ 1,508 $ 3,890 $ 2,922
--------- -------- ---------- ---------
Operating expenses:
Research and
development 8,435 8,039 17,364 15,897

General and
administrative 4,480 2,908 7,722 5,722

Non-cash compensation
expense (income) (397) - (1,448) -

Restructure charge - (78) - (623)
--------- -------- ---------- ---------
Total operating
expenses 12,518 10,869 23,638 20,996
--------- -------- ---------- ---------
Operating loss (11,698) (9,361) (19,748) (18,074)

Other income
(expense): (1,710) 554 (12,690) 519
--------- -------- ---------- ---------
Loss from continuing
operations, before
cumulative effect,
gain from sale
of subsidiary and
discontinued
operations (13,408) (8,807) (32,438) (17,555)

Cumulative effect of
a change in
accounting policy - - 972 -

Gain from sale
of subsidiary - 32,987 - 32,987

Loss from
discontinued operations - (2,785) - (2,529)
--------- -------- ---------- ---------
Net (loss)/income $ (13,408) $ 21,395 $ (31,466) $ 12,903
========= ======== ========== =========

Basic and diluted
net loss per share
from continuing
operations $ (0.36) $ (0.25) $ (0.87) $ (0.52)
Basic and diluted
net loss per share
from cumulative
effect of a change
in accounting
policy $ - $ - $ 0.03 $ -
Basic and diluted
earnings per share
from gain on sale
of subsidiary $ - $ 0.94 $ - $ 0.98
Basic and diluted
net loss per share
from discontinued
segments $ - $ (0.08) $ - $ (0.08)
--------- -------- ---------- ---------
Basic and diluted
net loss
per share $ (0.36) $ 0.61 $ (0.84) $ 0.38
========= ======== ========== =========
Shares used in
computing basic
and diluted net
loss per share 37,611 35,289 37,480 33,678

* The 2000 results of the Company`s former subsidiaries, Axys Advanced
Technologies and PPGx, have been reclassified in accordance with APB
30 Reporting the Results of Operations

Condensed Balance Sheet Data

June 30, December 31,
2001 2000
(unaudited)
----------------- --------------
(in thousands)

Cash, cash equivalents & marketable
investments (includes $4.0M of
restricted cash) $ 20,827 $ 41,776

Total assets 99,244 118,696

Accumulated deficit (298,821) (267,355)

Total stockholders` equity 59,695 79,565



CONTACT: Axys Pharmaceuticals, Inc.
Paul J. Hastings, 650/829-1000

MfG, principale